logo

Evofem Biosciences Inc. (EVFM)



Trade EVFM now with
  Date
  Headline
6/16/2022 8:49:46 AM Evofem Says Phexxi Prevented 99% Of Pregnancies Per Act Of Intercourse In Post Hoc Analysis Of Phase 3 Trial Data
6/2/2022 8:49:27 AM Evofem Biosciences: FDA Extends Shelf Life Of Phexxi From Three To Four Years
5/20/2022 9:17:12 AM Evofem Biosciences Announces Pricing Of About $26.6 Mln Public Offering
5/5/2022 9:02:49 AM Evofem Biosciences Announces 1-for-15 Reverse Stock Split
5/5/2022 9:00:00 AM Evofem Biosciences Announces 1-for-15 Reverse Stock Split (Press Release)
4/19/2022 6:55:38 AM Journal Of Sexual Medicine Publishes Data Collected From Evofem's Phase 3 AMPOWER Clinical Trial
4/11/2022 6:55:23 AM Evofem Announces Karina Fedasz As New Head Of Business Development
4/7/2022 6:51:14 AM Nasdaq Accepts Evofem Plan To Regain Listing Compliance
3/4/2022 6:49:18 AM Evofem Closes Enrollment In EVOGUARD Phase 3 Trial Of EVO100 For Prevention Of Chlamydia And Gonorrhea In Women
1/19/2022 9:03:09 AM Evofem Biosciences Reports 81% Increase In Phexxi Units Dispensed
12/16/2021 7:14:27 AM Evofem Biosciences And Orion Biotechnology Collaborate To Develop MPT Product Candidate To Include HIV Prevention
11/30/2021 8:11:57 AM Evofem Biosciences Reports Successful Type C Meeting With FDA For STI Prevention Product Candidate
11/22/2021 6:51:30 AM Evofem Biosciences Says Successfully Extends Cumulative Net Sales Covenant Timing To June 30, 2023
11/10/2021 7:13:45 AM Evofem Biosciences Announces Regulatory Submission In Mexico For Hormone-Free Contraceptive